A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host Disease (GVHD)
Public ClinicalTrials.gov record NCT07913672. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pilot Study of Live Biotherapeutic Product (LBP) MARCO (Microbiota Augmentation to Reestablish Commensal Organisms) Combined With Ruxolitinibfor Patients With Steroid Refractory or Intolerant Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) After Allogeneic Cell Transplantation (Allo-HCT) (MARCO-GVHD Trial)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The researchers are doing this study to find out whether the combination of LBP-MARCO (Microbiota Augmentation to Reestablish Commensal Organisms) and ruxolitinib is a safe treatment for people with graft-versus-host disease (GVHD) after receiving a stem cell (allogeneic hematopoietic cell transplantation).
Study identification
- NCT ID
- NCT07913672
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 16 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 27, 2026 (Actual)
- Primary completion
- Oct 27, 2028 (Estimated)
- Completion
- Oct 27, 2028 (Estimated)
- Last update posted
- Nov 3, 2026
2026 – 2028
United States locations
- U.S. sites
- 7
- U.S. states
- 2
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge (Consent Only) | Basking Ridge | New Jersey | 07920 | Recruiting |
| Memorial Sloan Kettering Monmouth (Consent Only) | Middletown | New Jersey | 07748 | Recruiting |
| Memorial Sloan Kettering Bergen (Consent Only) | Montvale | New Jersey | 07645 | Recruiting |
| Memorial Sloan Kettering Suffolk-Commack (Consent Only) | Commack | New York | 11725 | Recruiting |
| Memorial Sloan Kettering Westchester (Consent Only) | Harrison | New York | 10604 | Recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York | New York | 10065 | Recruiting |
| Memorial Sloan Kettering Nassau (Consent Only) | Rockville Centre | New York | 11553 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07913672, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 3, 2026 · Synced Nov 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07913672 live on ClinicalTrials.gov.